Gary Nachman
Stock Analyst at Canaccord Genuity
(3.58)
# 1,261
Out of 5,182 analysts
107
Total ratings
56.41%
Success rate
4.53%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Initiates: Buy | $262 | $197.38 | +32.74% | 18 | Apr 21, 2026 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $62 | $46.29 | +33.94% | 6 | Apr 21, 2026 | |
| IONS Ionis Pharmaceuticals | Initiates: Buy | $110 | $72.23 | +52.29% | 5 | Apr 21, 2026 | |
| ADMA ADMA Biologics | Initiates: Buy | $21 | $10.93 | +92.13% | 1 | Apr 21, 2026 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $13 | $3.96 | +228.28% | 2 | Apr 21, 2026 | |
| AMGN Amgen | Initiates: Hold | $366 | $340.18 | +7.59% | 3 | Apr 21, 2026 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $15.88 | +19.65% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $9.76 | +412.30% | 3 | Oct 20, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.34 | +754.70% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $11.74 | +138.50% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $298 | $308.51 | -3.41% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $37 | $25.55 | +44.81% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.10 | +70.73% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $201.22 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.57 | -68.18% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $11.59 | +158.84% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.16 | +669.23% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $14.81 | -5.47% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.60 | +681.25% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $31.26 | -68.01% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $30.51 | -1.67% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.58 | +16,275.55% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.58 | +43.37% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $21.65 | -3.00% | 5 | May 11, 2020 |
AbbVie
Apr 21, 2026
Initiates: Buy
Price Target: $262
Current: $197.38
Upside: +32.74%
Scholar Rock Holding
Apr 21, 2026
Initiates: Buy
Price Target: $62
Current: $46.29
Upside: +33.94%
Ionis Pharmaceuticals
Apr 21, 2026
Initiates: Buy
Price Target: $110
Current: $72.23
Upside: +52.29%
ADMA Biologics
Apr 21, 2026
Initiates: Buy
Price Target: $21
Current: $10.93
Upside: +92.13%
Achieve Life Sciences
Apr 21, 2026
Initiates: Buy
Price Target: $13
Current: $3.96
Upside: +228.28%
Amgen
Apr 21, 2026
Initiates: Hold
Price Target: $366
Current: $340.18
Upside: +7.59%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $15.88
Upside: +19.65%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $9.76
Upside: +412.30%
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.34
Upside: +754.70%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.74
Upside: +138.50%
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $308.51
Upside: -3.41%
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.55
Upside: +44.81%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.10
Upside: +70.73%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $201.22
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.57
Upside: -68.18%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $11.59
Upside: +158.84%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.16
Upside: +669.23%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $14.81
Upside: -5.47%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.60
Upside: +681.25%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $31.26
Upside: -68.01%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $30.51
Upside: -1.67%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.58
Upside: +16,275.55%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.58
Upside: +43.37%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $21.65
Upside: -3.00%